The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus
- PMID:10974601
- DOI: 10.1016/s0924-977x(00)00087-0
The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus
Abstract
The serotonergic activity in hippocampus was investigated following acute and chronic treatment with the antipsychotic drugs haloperidol and risperidone. Acute administration of risperidone, the serotonin(2) (5-HT(2)) receptor antagonist ketanserin, and the dopamine (DA)-D(2) receptor antagonist raclopride increased the 5-hydroxyindoleacetic acid/serotonin (5-HIAA/5-HT) ratio. In contrast, acute administration of haloperidol did not affect this ratio. Chronic administration of risperidone maintained the increased 5-HIAA/5-HT ratio; a challenge dose of risperidone after the chronic treatment and the subsequent washout period also maintained the increased ratio. Chronic administration of haloperidol as well as a challenge dose of haloperidol following chronic treatment did not affect the serotonergic activity in hippocampus. Administration of ketanserin or raclopride after chronic treatment and the washout period induced an additional increase in the 5-HIAA/5-HT ratio in risperidone-treated rats. Moreover, a challenge dose of ketanserin, but not raclopride, increased the 5-HIAA/5-HT ratio in haloperidol-treated rats. The present results indicate that acute and chronic treatment of haloperidol or risperidone modified serotonergic activity in the hippocampus in a different way. Moreover, the augmentation of serotonergic activity induced by risperidone did not seem to be solely related to dopaminergic or serotonergic properties and may be of particular relevance for the amelioration of schizophrenia symptoms.
Similar articles
- Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.Hertel P, Nomikos GG, Iurlo M, Svensson TH.Hertel P, et al.Psychopharmacology (Berl). 1996 Mar;124(1-2):74-86. doi: 10.1007/BF02245607.Psychopharmacology (Berl). 1996.PMID:8935802
- 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.Li Z, Huang M, Prus AJ, Dai J, Meltzer HY.Li Z, et al.Brain Res. 2007 Feb 23;1134(1):70-8. doi: 10.1016/j.brainres.2006.11.060. Epub 2007 Jan 4.Brain Res. 2007.PMID:17207474
- Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.Markianos M, Hatzimanolis J, Lykouras L.Markianos M, et al.Psychopharmacology (Berl). 2001 Aug;157(1):55-9. doi: 10.1007/s002130100768.Psychopharmacology (Berl). 2001.PMID:11512043
- Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus.Adams W, van den Buuse M.Adams W, et al.Neuropharmacology. 2011 Sep;61(3):458-67. doi: 10.1016/j.neuropharm.2011.03.018. Epub 2011 Apr 5.Neuropharmacology. 2011.PMID:21477601
- The Effects of Four Compounds That Act on the Dopaminergic and Serotonergic Systems on Working Memory in Animal Studies; A Literature Review.Grosu ȘA, Chirilă M, Rad F, Enache A, Handra CM, Ghiță I.Grosu ȘA, et al.Brain Sci. 2023 Mar 25;13(4):546. doi: 10.3390/brainsci13040546.Brain Sci. 2023.PMID:37190512Free PMC article.Review.
Cited by
- Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?Möller HJ.Möller HJ.Eur Arch Psychiatry Clin Neurosci. 2005 Jun;255(3):190-201. doi: 10.1007/s00406-005-0587-5.Eur Arch Psychiatry Clin Neurosci. 2005.PMID:15995903Review.
- The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.Weiner I.Weiner I.Psychopharmacology (Berl). 2003 Sep;169(3-4):257-97. doi: 10.1007/s00213-002-1313-x. Epub 2003 Feb 25.Psychopharmacology (Berl). 2003.PMID:12601500Review.
- Nicotinic-serotonergic drug interactions and attentional performance in rats.Rezvani AH, Caldwell DP, Levin ED.Rezvani AH, et al.Psychopharmacology (Berl). 2005 May;179(3):521-8. doi: 10.1007/s00213-004-2060-y. Epub 2005 Jan 29.Psychopharmacology (Berl). 2005.PMID:15682310
- A New Look on an Old Issue: Comprehensive Review of Neurotransmitter Studies in Cerebrospinal Fluid of Patients with Schizophrenia and Antipsychotic Effect on Monoamine's Metabolism.Gasnier M, Ellul P, Plaze M, Ahad PA.Gasnier M, et al.Clin Psychopharmacol Neurosci. 2021 Aug 31;19(3):395-410. doi: 10.9758/cpn.2021.19.3.395.Clin Psychopharmacol Neurosci. 2021.PMID:34294610Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources